Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial)

Launched by JANJIRA PETSUKSIRI · Apr 27, 2024

Keywords

ClinConnect Summary

The OraGO-1 Trial is studying a new way to treat Graves' ophthalmopathy, a condition that causes swelling and inflammation around the eyes, often leading to discomfort and vision problems. The trial is comparing two different lengths of radiation therapy treatment to see if a shorter schedule of 5 sessions is just as effective as the standard 10 sessions in helping reduce symptoms and improve patients' quality of life. This treatment is aimed at adults aged 35 and older who have moderate to severe thyroid eye disease and have not responded well to steroid treatments.

If you or a loved one is struggling with this condition, you might be eligible to join the trial if you have active symptoms and have not seen improvement after receiving steroid treatments. Participants will receive targeted radiation therapy along with supportive care and will be monitored throughout the study. It's important to know that this trial is currently recruiting and is open to both men and women, but individuals with certain medical conditions, like severe high blood pressure or diabetes-related eye problems, will not be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with active moderate to severe thyroid eye disease with a CAS \> 4 with/ without diplopia before starting IVMP
• • Patient with poor response to 3 doses of IVMP (CAS drop \< 1) หรือ CAS score \> 3 after 3 doses of IVMP
• • Patients with diplopia after 3 doses of IVMP
• • Patients with Graves' Ophthalmopathy who have maintained euthyroidism
• • Non-pregnant adults (aged 35 years or older)
• Exclusion Criteria:
• • Individuals with severe hypertension or diabetic retinopathy